Osteosarcoma

NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...

New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...

NEW YORK, NEW YORK, UNITED STATES — February 17, 2026 OS Therapies has announced a major global regulatory update...

NEW YORK, NY — December 5, 2025 — OS Therapies Inc. announced two major regulatory milestones advancing its lead...

Dateline: November 17, 2025 — New York, NYOS Therapies reported its third-quarter 2025 financial results and issued a comprehensive...

New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...